Evidence-based Definition for Extensively Drug-Resistant Tuberculosis
Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendat...
Saved in:
| Published in: | American journal of respiratory and critical care medicine Vol. 204; no. 6; p. 713 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
15.09.2021
|
| ISSN: | 1535-4970, 1535-4970 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63-2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20-0.69) with linezolid only, 0.40 (95% CI, 0.21-0.77) with bedaquiline only, and 0.21 (95% CI, 0.12-0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice.Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63-2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20-0.69) with linezolid only, 0.40 (95% CI, 0.21-0.77) with bedaquiline only, and 0.21 (95% CI, 0.12-0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice. |
|---|---|
| AbstractList | Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63-2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20-0.69) with linezolid only, 0.40 (95% CI, 0.21-0.77) with bedaquiline only, and 0.21 (95% CI, 0.12-0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice.Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB [MDR-TB]), any fluoroquinolone (FQ), and any second-line injectable drug (SLID). In 2019, the World Health Organization issued new recommendations for treating patients with drug-resistant TB, substantially limiting the role of SLIDs in MDR-TB treatment and thus putting the definition of XDR-TB into question. Objectives: To propose an up-to-date definition for XDR-TB. Methods: We used a large data set to assess treatment outcomes for patients with MDR-TB exposed to any type of longer regimen. We included patients with bacteriologically confirmed MDR-TB and known FQ and SLID resistance results. We performed logistic regression to estimate the adjusted odds ratios (aORs) for an unfavorable treatment outcome (failure, relapse, death, loss to follow-up), and estimates were stratified by the resistance pattern (FQ and/or SLID) and group A drug use (moxifloxacin/levofloxacin, linezolid, and/or bedaquiline). Measurements and Main Results: We included 11,666 patients with MDR-TB; 4,653 (39.9%) had an unfavorable treatment outcome. Resistance to FQs increased the odds of an unfavorable treatment outcome (aOR, 1.91; 95% confidence interval [CI], 1.63-2.23). Administration of bedaquiline and/or linezolid improved treatment outcomes regardless of resistance to FQs and/or SLIDs. Among patients with XDR-TB, compared with persons receiving no group A drug, aORs for an unfavorable outcome were 0.37 (95% CI, 0.20-0.69) with linezolid only, 0.40 (95% CI, 0.21-0.77) with bedaquiline only, and 0.21 (95% CI, 0.12-0.38) with both. Conclusions: Our study supports a new definition of XDR-TB as MDR-TB and additional resistance to FQ plus bedaquiline and/or linezolid and helps assess the adequacy of this definition for surveillance and treatment choice. |
| Author | Guglielmetti, Lorenzo Keiser, Olivia Raviglione, Mario Menzies, Dick Cegielski, J Peter Lienhardt, Christian Sotgiu, Giovanni Campbell, Jonathon R Palmero, Domingo Bang, Didi Fox, Greg J Tiberi, Simon Roelens, Maroussia Lange, Christoph Estill, Janne Battista Migliori, Giovanni Rozanova, Liudmila Brust, James C M |
| Author_xml | – sequence: 1 givenname: Maroussia surname: Roelens fullname: Roelens, Maroussia – sequence: 2 givenname: Giovanni surname: Battista Migliori fullname: Battista Migliori, Giovanni – sequence: 3 givenname: Liudmila surname: Rozanova fullname: Rozanova, Liudmila – sequence: 4 givenname: Janne surname: Estill fullname: Estill, Janne – sequence: 5 givenname: Jonathon R surname: Campbell fullname: Campbell, Jonathon R – sequence: 6 givenname: J Peter surname: Cegielski fullname: Cegielski, J Peter – sequence: 7 givenname: Simon surname: Tiberi fullname: Tiberi, Simon – sequence: 8 givenname: Domingo surname: Palmero fullname: Palmero, Domingo – sequence: 9 givenname: Greg J surname: Fox fullname: Fox, Greg J – sequence: 10 givenname: Lorenzo surname: Guglielmetti fullname: Guglielmetti, Lorenzo – sequence: 11 givenname: Giovanni surname: Sotgiu fullname: Sotgiu, Giovanni – sequence: 12 givenname: James C M surname: Brust fullname: Brust, James C M – sequence: 13 givenname: Didi surname: Bang fullname: Bang, Didi – sequence: 14 givenname: Christian surname: Lienhardt fullname: Lienhardt, Christian – sequence: 15 givenname: Christoph surname: Lange fullname: Lange, Christoph – sequence: 16 givenname: Dick surname: Menzies fullname: Menzies, Dick – sequence: 17 givenname: Olivia surname: Keiser fullname: Keiser, Olivia – sequence: 18 givenname: Mario surname: Raviglione fullname: Raviglione, Mario |
| BookMark | eNpNjMtKAzEYRoNUsK2-gKtZuknNtUmW0o5VKBSkrksufyQyzegkU_TtLehC-OAczuKboUnuMyB0S8mC0qW4H7w_LhhhhBjMJVO71QWaUsklFkaRyT-_QrNS3gmhTFMyRW17SgGyB-xsgdCsIaacaupzE_uhab8q5JJO0H0362F8wy9QUqk212Y_Ohj82PXncI0uo-0K3Pxxjl4f2_3qCW93m-fVwxZ7LljFkStwGsTSSG0sMCO5l0E7FbjTTDinVVQxGiHCec4q6wgoKqMPDgIENkd3v78fQ_85QqmHYyoeus5m6MdyYJIbrTVRkv0AIPVT-g |
| CitedBy_id | crossref_primary_10_1016_j_cmi_2022_07_026 crossref_primary_10_1128_msphere_00369_22 crossref_primary_10_1016_j_cmi_2023_02_013 crossref_primary_10_1016_S1473_3099_22_00875_1 crossref_primary_10_1128_spectrum_01392_23 crossref_primary_10_1055_a_1939_0000 crossref_primary_10_3201_eid3003_240134 crossref_primary_10_3201_eid2809_220458 crossref_primary_10_1186_s13073_022_01054_6 crossref_primary_10_1099_mgen_0_000740 crossref_primary_10_1080_22221751_2024_2399273 crossref_primary_10_1016_j_lanepe_2025_101380 crossref_primary_10_3390_ijms241210302 crossref_primary_10_1080_14787210_2024_2303032 crossref_primary_10_1016_j_arbres_2022_07_012 crossref_primary_10_1186_s12879_023_08413_7 crossref_primary_10_5588_ijtldopen_24_0325 crossref_primary_10_1134_S002626172360444X crossref_primary_10_3201_eid3004_231732 crossref_primary_10_1186_s12879_024_09036_2 |
| ContentType | Journal Article |
| DBID | 7X8 |
| DOI | 10.1164/rccm.202009-3527OC |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1535-4970 |
| GroupedDBID | --- -~X .55 0R~ 23M 2WC 34G 39C 53G 5GY 5RE 7RV 7X7 7X8 8C1 8FW 8R4 8R5 AAQQT AAWTL ABJNI ABOCM ABPMR ACGFO ACGFS ADBBV AENEX AFCHL AHMBA ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BPHCQ C45 CS3 DIK E3Z EBS EJD EMOBN EX3 F5P FRP GX1 H13 HZ~ IH2 J5H KQ8 L7B M5~ O9- OBH OFXIZ OGEVE OK1 OVD OVIDX P2P PCD PQQKQ Q2X RWL SJN TAE TEORI THO TR2 W8F WH7 WOQ WOW X7M YJK ~02 |
| ID | FETCH-LOGICAL-c342t-f37eb8e469589ae2953c5d8b7d3b824bb87f7ff944d44dba7ab0e715fcdbeded2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 24 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000699724500016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1535-4970 |
| IngestDate | Fri Sep 05 06:49:30 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c342t-f37eb8e469589ae2953c5d8b7d3b824bb87f7ff944d44dba7ab0e715fcdbeded2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 2539888075 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2539888075 |
| PublicationCentury | 2000 |
| PublicationDate | 20210915 |
| PublicationDateYYYYMMDD | 2021-09-15 |
| PublicationDate_xml | – month: 09 year: 2021 text: 20210915 day: 15 |
| PublicationDecade | 2020 |
| PublicationTitle | American journal of respiratory and critical care medicine |
| PublicationYear | 2021 |
| SSID | ssj0012810 |
| Score | 2.4934716 |
| Snippet | Rationale: Until 2020, extensively drug-resistant tuberculosis (XDR-TB) was defined as TB with resistance to rifampicin and isoniazid (multidrug-resistant TB... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | 713 |
| Title | Evidence-based Definition for Extensively Drug-Resistant Tuberculosis |
| URI | https://www.proquest.com/docview/2539888075 |
| Volume | 204 |
| WOSCitedRecordID | wos000699724500016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7UinjxLb6J4HVp3Ed3cxLpAy9WkQq9lczurBRKokkj-u_dTVN68CIIOYUcwj5mvtnvm_0IuRFcWwkqpqgNUCEZUC1AU2uUSmPkII2uzSbUcKjH4-S5OXArG1nlMibWgdrmJpyRt5nkia_WfIa7e_-gwTUqsKuNhcY6aXEPZYKkS41XLALTi9sIJJfBSS1eNs10RLswJvSh19yAxyDqqfsrGNcZZrD733_bIzsNtozuF4thn6xhdkC2Hhv2_JD0lxaiNOQuG_XQTbNashV56Br1vxo1--w76hXVG33BMqDLbB6NKsDCVLPcvzgir4P-qPtAGxsFarhgc-q4QtDo62CpkxRZIrmRVoOyHDQTAFo55VwihPUPpCqFGNWtdMYCWrTsmGxkeYYnJALhJ1wxdCg7QhuRJmmc2ESDr3O4c_qUXC8HaOKXaeAe0gzzqpyshujsD9-ck20WtCPBqkFekJbzWxEvyab5nE_L4qqe5R-fl7O6 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evidence-based+Definition+for+Extensively+Drug-Resistant+Tuberculosis&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Roelens%2C+Maroussia&rft.au=Battista+Migliori%2C+Giovanni&rft.au=Rozanova%2C+Liudmila&rft.au=Estill%2C+Janne&rft.date=2021-09-15&rft.issn=1535-4970&rft.eissn=1535-4970&rft.volume=204&rft.issue=6&rft.spage=713&rft_id=info:doi/10.1164%2Frccm.202009-3527OC&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-4970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-4970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-4970&client=summon |